ImageneBio (IMA) FDA Approvals $5.51 0.00 (0.00%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings ImageneBio's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by ImageneBio (IMA). Over the past two years, ImageneBio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as IMG-007. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. IMG-007 FDA Regulatory Events IMG-007 is a drug developed by ImageneBio for the following indication: adults with moderate-to-severe AD, recruiting both biologic- and/or JAK inhibitor-experienced and naive patients. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - November 12,2025Provided Update Drug: IMG-007Announced Date: November 12, 2025Indication: adults with moderate-to-severe AD, recruiting both biologic- and/or JAK inhibitor-experienced and naive patients.AnnouncementImageneBio, Inc. announced financial results for the quarter ended September 30, 2025, and provided an update on its program.AI SummaryImageneBio reported third-quarter 2025 results and an update on its IMG-007 program. The company ended September 30, 2025 with $142.6 million in cash, cash equivalents and marketable securities, largely driven by a merger and a $75 million private placement. Quarterly R&D expense was $15.6 million, G&A $11.0 million, and net loss was $24.8 million. Imagene announced a planned protocol amendment for its ongoing Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis to better match IMG-007’s molecular profile. The amendment aims to broaden dose ranges, evaluate loading doses and patient-friendly dosing intervals, and improve study feasibility. Enrollment at North American sites remains strong and topline data are expected in 2027. Imagene will present Phase 1b/2a data at the ISDS meeting showing a dose-related hair regrowth signal and suppressed scalp inflammatory biomarkers in alopecia areata, and strong EASI improvements in atopic dermatitis. The company also strengthened leadership with new executive hires and a new independent director.Read Announcement ImageneBio FDA Events - Frequently Asked Questions Has ImageneBio received FDA approval? As of now, ImageneBio (IMA) has not received any FDA approvals for its therapy in the last two years. What drugs has ImageneBio submitted to the FDA? In the past two years, ImageneBio (IMA) has reported FDA regulatory activity for IMG-007. What is the most recent FDA event for ImageneBio? The most recent FDA-related event for ImageneBio occurred on November 12, 2025, involving IMG-007. The update was categorized as "Provided Update," with the company reporting: "ImageneBio, Inc. announced financial results for the quarter ended September 30, 2025, and provided an update on its program." What conditions do ImageneBio's current drugs treat? Currently, ImageneBio has one therapy (IMG-007) targeting the following condition: adults with moderate-to-severe AD, recruiting both biologic- and/or JAK inhibitor-experienced and naive patients.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Takeda Pharmaceutical FDA EventsScholar Rock FDA EventsAC Immune FDA EventsAlector FDA EventsAlzamend Neuro FDA EventsArcutis Biotherapeutics FDA EventsBioNTech FDA EventsHarrow FDA EventsIonis Pharmaceuticals FDA EventsMilestone Pharmaceuticals FDA EventsRadiopharm Theranostics FDA EventsRein Therapeutics FDA EventsTurn Therapeutics FDA EventsNuvation Bio FDA EventsHumacyte FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Greenwich LifeSciences FDA Events Akebia Therapeutics FDA Events Capricor Therapeutics FDA Events Alector FDA Events Compugen FDA Events Emergent Biosolutions FDA Events Organogenesis FDA Events Innate Pharma FDA Events Keros Therapeutics FDA Events Protara Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:IMA last updated on 11/12/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - November 12,2025Provided Update Drug: IMG-007Announced Date: November 12, 2025Indication: adults with moderate-to-severe AD, recruiting both biologic- and/or JAK inhibitor-experienced and naive patients.AnnouncementImageneBio, Inc. announced financial results for the quarter ended September 30, 2025, and provided an update on its program.AI SummaryImageneBio reported third-quarter 2025 results and an update on its IMG-007 program. The company ended September 30, 2025 with $142.6 million in cash, cash equivalents and marketable securities, largely driven by a merger and a $75 million private placement. Quarterly R&D expense was $15.6 million, G&A $11.0 million, and net loss was $24.8 million. Imagene announced a planned protocol amendment for its ongoing Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis to better match IMG-007’s molecular profile. The amendment aims to broaden dose ranges, evaluate loading doses and patient-friendly dosing intervals, and improve study feasibility. Enrollment at North American sites remains strong and topline data are expected in 2027. Imagene will present Phase 1b/2a data at the ISDS meeting showing a dose-related hair regrowth signal and suppressed scalp inflammatory biomarkers in alopecia areata, and strong EASI improvements in atopic dermatitis. The company also strengthened leadership with new executive hires and a new independent director.Read Announcement
Free IMA Stock Alerts